Morepen Laboratories
NSE: MOREPENLAB · BSE 500288 · 13 Aug 2026 · Sabarinadh Palutla
BBB
Constructive on the business, cautious on the price
Gatekeeper driver: Governance / ownership, not operations
Summary
A pharma business at a genuine growth inflection — a ₹825cr CDMO mandate, a medical-devices demerger and Q1 FY27 revenue up 36% — priced richly enough that the entry point matters more than the thesis. The Gatekeeper reads AMBER on governance and ownership rather than operations: promoter holding is 35.65% with nil pledge, but a KMP resignation in July 2026 sits on the file. Valuation does not reconcile across data vendors, which is itself worth knowing.
Component scores
All component scores and the composite are KIRA analysis ^.
| Component | Weight | Score ^ |
|---|---|---|
| Fundamentals | 25% | 68 |
| Business Quality | 20% | 66 |
| Management | 20% | 58 |
| Institutional (FII/DII) | 10% | 45 |
| Financial Strength | 10% | 65 |
| Valuation | 5% | 48 |
| Technicals | 5% | 62 |
| Risk | 5% | 55 |
| Composite KIRA Score ^ | 100% | 61.8 |
Strengths
- ₹825cr CDMO mandate materially changes the revenue base
- Medical Devices demerger clarifies the structure
- Q1 FY27 revenue up 36% — growth inflection is visible in the numbers
- Promoter holding 35.65% with nil pledge
Weaknesses
- Rich valuation, and it does not reconcile across vendors (~29–46x) ^
- Thin institutional base at roughly 2.7%
- KMP resignation in July 2026
Risks
- Regulatory and quality risk across API and formulations
- CDMO mandate concentration — execution on one large contract
- Thin institutional ownership means limited external scrutiny and thinner liquidity
- Valuation dispersion across vendors suggests the earnings base is not settled
Provenance. Unmarked figures are sourced from filings, results, rating actions or screeners. ^ denotes KIRA analysis. ? denotes an unverified inference. Grade bands are provisional.
KIRA Markets provides research and financial education only. KIRA is not registered with SEBI as a Research Analyst and does not provide personalised investment advice. Nothing published here is a recommendation, offer or solicitation to buy or sell any security. Investing in securities carries risk, including loss of principal. Past performance is not indicative of future results. Readers should consult a SEBI-registered adviser before making investment decisions.